144 related articles for article (PubMed ID: 34009323)
1. Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness.
Hageman SHJ; Dorresteijn JAN; Bots ML; Asselbergs FW; Westerink J; van der Meulen MP; Mosterd A; Visseren FLJ; ; Asselbergs FW; Nathoe HM; de Borst GJ; Bots ML; Geerlings MI; Emmelot MH; de Jong PA; Leiner T; Lely AT; van der Kaaij NP; Kappelle LJ; Ruigrok YM; Verhaar MC; Visseren FLJ; Westerink J
Eur J Prev Cardiol; 2022 Mar; 29(4):635-644. PubMed ID: 34009323
[TBL] [Abstract][Full Text] [Related]
2. Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
Berkelmans GFN; Greving JP; van der Graaf Y; Visseren FLJ; Dorresteijn JAN
Diagn Progn Res; 2020; 4():4. PubMed ID: 32318625
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Mediterranean diet and physical activity in secondary CVD prevention: results from the UCC-SMART cohort study.
Bonekamp NE; Visseren FLJ; van der Schouw YT; van der Meer MG; Teraa M; Ruigrok Y; Geleijnse JM; Koopal C;
Eur J Prev Cardiol; 2024 Mar; ():. PubMed ID: 38547043
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
11. Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.
Kohli-Lynch CN; Lewsey J; Boyd KA; French DD; Jordan N; Moran AE; Sattar N; Preiss D; Briggs AH
Circulation; 2022 Apr; 145(17):1312-1323. PubMed ID: 35249370
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.
Stam-Slob MC; van der Graaf Y; Greving JP; Dorresteijn JA; Visseren FL
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214794
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study.
Si S; Moss J; Karnon J; Stocks N
PLoS One; 2018; 13(11):e0207110. PubMed ID: 30412596
[TBL] [Abstract][Full Text] [Related]
14. Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis.
Perera K; Kam N; Ademi Z; Liew D; Zomer E
J Clin Lipidol; 2020; 14(6):772-783. PubMed ID: 32994152
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
[TBL] [Abstract][Full Text] [Related]
16. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
Wang M; Liu J; Bellows BK; Qi Y; Sun J; Liu J; Moran AE; Zhao D
Glob Heart; 2020 Jun; 15(1):43. PubMed ID: 32923337
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
Kumar R; Tonkin A; Liew D; Zomer E
Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C;
Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925
[TBL] [Abstract][Full Text] [Related]
20. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling.
Perera R; McFadden E; McLellan J; Lung T; Clarke P; Pérez T; Fanshawe T; Dalton A; Farmer A; Glasziou P; Takahashi O; Stevens J; Irwig L; Hirst J; Stevens S; Leslie A; Ohde S; Deshpande G; Urayama K; Shine B; Stevens R
Health Technol Assess; 2015 Dec; 19(100):1-401, vii-viii. PubMed ID: 26680162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
